Search results (203)
« Back to NewsThe latest news, updates and announcements from the Nuffield Department of Medicine.
Research finds new metabolic clues to survival in tuberculous meningitis
12 June 2025
In a collaborative new study led by OUCRU, researchers have found that tryptophan in cerebrospinal fluid is a determinant of lower survival in people with tuberculous meningitis. These findings suggest the possibility that other metabolites could also predict patient outcomes.
Nipah virus vaccine granted European Medicines Agency PRIME designation
11 June 2025
Co-led by researchers at the Pandemic Sciences Institute, the Nipah virus has been granted PRIME designation. This recognises the vaccine’s potential to address the unmet medical need arising from the devastating Nipah virus disease, which can be fatal in up to 85% of cases.
Unlocking the potential of genetic data for research and healthcare
5 June 2025
Researchers at the Big Data Institute have announced a new data format designed to unlock the potential of the millions of genomes now sequenced in global healthcare systems.
PSI publish first validated tool to measure stigma during disease outbreaks
4 June 2025
Researchers at the Pandemic Sciences Institute have published RAPID Stigma Scales to help health professionals monitor stigma in disease outbreak settings, improving outbreak responses globally.
New method reveals access to proteins in ancient human remains
29 May 2025
A new method, developed by researchers at the Nuffield Department of Medicine, could soon unlock the vast repository of biological information held in the proteins of ancient soft tissues. The findings, which could open up a new era for palaeobiological discovery, have been published in PLOS ONE.
Project to develop low-cost genome sequencing for pathogens launched
28 May 2025
A low-cost genome sequencing technique that was used by thousands of laboratories globally to spot COVID-19 variants will be extended to cover all pathogens, in an ambitious new Wellcome Trust-funded project launched today. The ARTIC-2 project is led by the University of Birmingham and brings together researchers from the Democratic Republic of Congo, Ghana and Kenya with expertise in responding to numerous viral threats using genomic surveillance, including recent outbreaks of Ebola virus and Mpox in Africa.
Molecule enabling new leukaemia treatments discovered
20 May 2025
Researchers at the Shi Lab have discovered a first-in-class LSD1 PROTAC degrader, which opens up new therapeutic paths for the treatment of acute myeloid leukaemia. PROTAC degraders are molecules that degrade proteins by using the cell’s own machinery, binding to both the target protein and an E3 ligase, which marks it for degradation by the proteasome.
T cell responses to monkeypox play a part in protecting against infection
13 May 2025
A new study, led by researchers at the NDM's CAMS Oxford Institute and the Centre for Human Genetics, TIDU in the MRC Weatherall Institute of Molecular Medicine, the Kennedy Institute and the Dunn School of Pathology, has found that specific T cells could have an impact on the long-term protective responses to future infection.
More effective and affordable treatment strategies for Hepatitis C
12 May 2025
NDM's Oxford University Clinical Research Unit (OUCRU) announced promising results from the VIETNARMS trial, a years-long multi-arm clinical trial conducted in Vietnam. The trial found that the readily available and affordable Hepatitis C treatment sofosbuvir/daclatasvir had a >95% cure rate. The results offer important insights into new treatment regimens for Hepatitis C, potentially reducing treatment durations and halving treatment costs.
Coeliac disease may be driven by immune structures in the gut
7 May 2025
Researchers in the Nuffield Department of Medicine have found structures of immune cells in the gut that may be driving the response to gluten in people with coeliac disease. These findings could provide a target for future therapies.
New guidelines published for monitoring IBD patients to prevent bowel cancer
2 May 2025
Led by NDM’s Professor James East, researchers and clinicians have developed major new guidelines for monitoring patients with inflammatory bowel disease (IBD) to prevent them going on to develop bowel cancer.
Common virus may improve skin cancer treatment outcomes
1 May 2025
May is Skin Cancer Awareness Month, and a new study with input from researchers in NDM’s units has revealed that a common virus may positively influence how skin cancer patients respond to current treatments.
New study confirms malaria drug safe for children and reduces disease burden
30 April 2025
A major study in The Lancet Infectious Diseases confirms that single low-dose primaquine is safe and effective in reducing malaria transmission in young children. Analysing data from over 6,000 patients, researchers found it effective even in young children and areas with high malaria burden.
Study finds that Treg depletion suppresses tumour growth
24 April 2025
A new study, co-lead by Dr Felipe Galvez-Cancino from the Centre for Immuno-Oncology, has shown that Treg cell depletion can suppress tumour growth in one of the deadliest types of cancer.
New combination therapy developed for acute myeloid leukaemia
17 April 2025
Researchers in the Shi group at Ludwig Cancer Research Oxford have developed a new combination therapy for acute myeloid leukaemia, showing therapeutic promise by promoting differentiation of immature blood cells.
Study identifies direct link between inflammation and asthma attacks
10 April 2025
An international consortium of respiratory scientists, including researchers from NDM’s Experimental Medicine Division, have shed light on the role of inflammation in asthma. Through their findings, they have provided a new way of predicting and preventing asthma attacks.
Up to £16.5 million awarded to global consortium to overcome obstacles in infectious disease research
9 April 2025
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has been awarded up to £16.5 million to build on its globally-recognised efforts to prevent illness and deaths from epidemic-prone infectious diseases.
Research team receive £5.5m in funding to transform bowel cancer care
1 April 2025
Cancer Research UK and partners have committed £5.5 million in funding to form a world-leading research team, co-led by NDM’s Professor Simon Leedham. The team’s goal is to make personalised medicine a reality for people with bowel cancer.
First human trial of aerosol vaccine delivery launched
27 March 2025
The Jenner Institute, in partnership with the Coler Lab at Seattle Children’s Research Institute (SCRI), is set to begin a new clinical trial to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-man aerosol mycobacterial challenge infection model with healthy adult volunteers.
Oxford marks World Tuberculosis Day as vaccine trials continue
24 March 2025
Thanks to cutting edge research at NDM's Jenner Institute and Oxford University Clinical Research Unit (OUCRU), Oxford remains at the forefront of research to develop new vaccines to protect against this devastating disease.